For citations:

Eliseev M.S., Barskova V.G., Nasonov E.L. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Rheumatology Science and Practice. 2013;51(4):428-431. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1255